STAT1

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on: 
Monday, March 25, 2024
CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
  • Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
  • LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
  • Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

Retrieved on: 
Tuesday, January 16, 2024
Mortality, Neoplasm, Patient, CD163, JAK1, Therapy, Research, Survival, Cancer, CD86, TGF-B2, OTCQB, STAT1, APC, HR, CD14, TGFB2, Interferon gamma, Messenger, TME, DMG, Glioma, Vaccine

We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

Key Points: 
  • We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
  • IFNGR2 is a critical component of the IFN-γ signaling pathway, playing a significant role in mediating the immune system's defense against cancer.
  • The expression levels of IFNGR2 and TGFB2 (1.51-fold increase (p = 0.002) and 1.58-fold increase (p = 5.5 × 10−4), respectively) were significantly upregulated in pbDMG tumors compared with normal brainstem/pons samples.
  • Worse survival outcomes in pbDMG patients when comparing high versus low TGFB2 levels in the context of low IFNGR2 levels suggest that the abrogation of the TGFB2 mRNA expression in the immunologically cold tumor microenvironment can be used to treat pbDMG patients.

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Cellular, Transplant, NPM1, Drug resistance, CD34, Exposition, STAT5, Bone marrow, Phosphorylation, RBC, CD71, Society, Therapy, MDS, Pharmacology, Ruxolitinib, ASH, Mutation, Coactivator (genetics), STAT1, Meeting, Syndrome, PST, Glycophorin A, Webcast, Patient, Safety, Acute myeloid leukemia, RVU, AML, DNA (cytosine-5)-methyltransferase 3A, Pharmaceutical industry

Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.

Key Points: 
  • Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.
  • The published clinical and non-clinical data strongly support RVU120’s Phase II development plans presented in October.
  • KRAKOW, Poland, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is held on December 9-12, 2023, in San Diego, California.
  • “The results from the CLI120-001 (RIVER-51) study of RVU120 in patients with r/r-AML and HR-MDS continue to improve over time.

Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit

Retrieved on: 
Tuesday, October 31, 2023
Drug development, Psoriasis, Haematopoiesis, SH2, STAT3, Parasitism, Deucravacitinib, Cytokine, Factorization of polynomials, Infection, Virus, JAK, Protein, STAT1, Immune system, Risk, Biology, Doctor of Pharmacy, Bacteria, Inflammation, Safety, Cancer, Src homology 2 domain containing f, TYK2, SAN, Pharmaceutical industry, Vaccine

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced that in a presentation given today at the 7th Annual Dermatology Drug Development Summit titled “Finding the New Ground Between Safety & Efficacy in Drug Development,” Recludix’s senior vice president of biology, Paul Smith, Ph.D., reviewed the challenges associated with inhibition of the JAK/STAT pathway through TYK2 and JAK inhibitors and presented preclinical data with Recludix’s STAT3 inhibitor REX-7117, which potently and selectively targets the STAT3 Src Homology 2 (SH2) domain. The presentation is available on the company’s website under the section titled “Events.”

Key Points: 
  • “Importantly, other approaches to inhibiting the JAK/STAT pathway by targeting TYK2 or JAK have resulted in undesirable safety consequences, such as increased risk of infections or altered hematopoiesis.
  • It provides durable STAT3 inhibition and maintains in vivo selectivity against other STAT proteins, even after the administration of multi-day oral dosing in a preclinical model.
  • In a translational Th17 preclinical model of psoriasis, once daily REX-7117 (300 mg/kg) was superior to a clinically-relevant dose of deucravacitinib (1 mg/kg).
  • Moreover, twice daily REX-7117 (300 mg/kg) was comparable to deucravacitinib at a supra-clinical dose (30 mg/kg), reinforcing the rationale of STAT3 targeting as a potential disease-modifying opportunity.

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology

Retrieved on: 
Thursday, July 13, 2023
DAMP, Biochemistry, Database, Nitration, STAT1, Tyrosine, Phosphorylation, HER2, Hsps, CCL2, Bioorganic chemistry, Enzyme, Cancer, CXCL12, Sirtuin 2, LCK, Human, SHP2, DSM-IV codes, BCL2, Protein, Journal, B cell, HDAC2, Cell, Drug discovery, JAK2, Histone deacetylase 2, Sirtuin 6, Therapy, Janus kinase 2, SIRT6, SIRT2, Medical imaging

Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.

Key Points: 
  • Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.
  • The analysis revealed three major cellular networks that could be impacted by tyrosine nitration, resulting in altered protein function, localization, turnover, and protein-protein interactions.
  • Known sites of tyrosine nitration are also sites of phosphorylation, suggesting an extensive role for nitration in cell signaling, such that tyrosine nitration could profoundly interfere or alternatively complement tyrosine phosphorylation.
  • Tyrosine nitration is associated with different types of cancer by altering metabolic reprogramming and signaling.

Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
RCC, Private Securities Litigation Reform Act, Risk, Abstract, Biomarker, Fast Track, Forward-looking statement, Large-cell lung carcinoma, Kidney, RECIST, Tumor microenvironment, AACR, Liver, Serum, Program, American Association, Hepatocellular carcinoma, Patient, Novartis, NSCLC, CD73, Surface, Chemokine, STAT1, Security (finance), GlaxoSmithKline, Association, American Association for Cancer Research, PVRIG, IL-27, Orphan drug, COVID-19, U.S. Securities and Exchange Commission, GLOBE, HCC, CD39, Annual report, FDA, CCR8, Medical imaging, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held in New Orleans, April 8-13, 2022.

Key Points: 
  • CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held in New Orleans, April 8-13, 2022.
  • We look forward to providing a clinical update on the program at a scientific conference later in the first half of 2022.
  • Summary of key SRF388 data:
    Pharmacokinetics (PK) from the dose-escalation phase of the SRF388 Phase 1 study were linear, with no dose-limiting toxicities reported.
  • As previously reported, one patient with squamous non-small-cell lung cancer experienced a confirmed partial response per RECIST v1.1 at this dose.

STAT Inhibitors Drug Pipeline Markets Research 2022: Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Apoptosis, News, Nausea, Discovery, Daewoong Pharmaceutical, Jiangsu Hengrui Medicine, STAT3, III, STAT5, Protein, Hepatic stellate cell, STAT5B, Acquisition, II, Infection, Clinical trial, STAT1, JAK3, STAT6, STAT5A, JAK2, COVID, STAT inhibitors, Niclosamide, Therapy, Oxidative phosphorylation, JAK1, Tyrosine, Oligonucleotide, Signal, STAT, Vomiting, Fatigue, JAK, Peptidomimetic, Pharmaceutical industry

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e.
  • The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D.